Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease ...Middle East

CARMIEL, Israel and BOSTON, April 4, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®...

Read More Details
Finally We wish PressBee provided you with enough information of ( Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease )

Also on site :

• Palestinians in Gaza are calling for their own ceasefire
• Shrimp and grit: Commercial fishermen, coastal legislators vow to spike proposed shrimping ban
• Nordstrom Rack Is Selling a Cutesy, Airy Dress and Shoppers are Lining Up to Buy It